Clinical trial · Interventional
Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma
NCT04288700CI-TRIAL-00043708unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Is to compare and evaluate the efficacy of oral captopril with oral propranolol, intralesional propranolol injection, and topical Timolol in the treatment of infantile hemangioma and their effect on vascular endothelial growth factor and CD 133.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Infantile Hemangioma | Infantile Hemangioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| intralesional propranolol injection | Drug | — | UNRESOLVED |
| Oral Captopril | Drug | — | UNRESOLVED |
| oral propranolol | Drug | — | UNRESOLVED |
| topical Timolol maleate 0.5% eye drops | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- Group A
- interventionNames
- Drug: oral propranolol
- type
- ACTIVE_COMPARATOR
- label
- Group B
- interventionNames
- Drug: Oral Captopril
- type
- ACTIVE_COMPARATOR
- label
- Group C
- interventionNames
- Drug: intralesional propranolol injection
- type
- ACTIVE_COMPARATOR
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Months
- Maximum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: * Pediatric patients younger than 12 years and older than 2 months of age with infantile hemangioma Exclusion Criteria: * Patient with ulcerated or infected hemangioma. * Patient younger than 2 months and older than 12 years of age. * Patients with multiple hemangiomas. * Any Patient with cardiovascular problems, bronchial asthma, diabetes mellitus, bilateral renal stenosis, Electrolyte disturbance, or renal impairment was excluded. * Patients with abnormal electrocardiogram, or echocardiogram should be excluded. * Patients who have had previous treatment for hemangioma.
References
Publications (0)
Data not yet available
No reference posted for this study.